Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: SiteTracker who wrote (14056)	3/24/2006 11:06:55 AM
From: russet	Read Replies (1) \| Respond to of 14101

An amazing post. Obviously not one from a card carrying cult member. Adding to one point a bit,...DMX never proved the mechanism of action of the DMSO carrier was the microtubule transport model. Alternative mechanisms that explain the clinical data are possible, and could lead the FDA to demand longer term studies. If DMSO disrupted normal cell waste removal mechanisms (exocytosis, membrane protein based removal pumps etc.) thereby favoring diffusion of Diclofenac from cell to cell via normal cell to cell membrane portals, there should be concern that other normal cell activities could be disrupted. The FDA was right to request longer term chronic pain studies especially in older subjects.